A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhodes Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2018 Results presented in a Purdue Pharma media release.
    • 01 Feb 2018 Primary endpoint (Change from Baseline in Clinician-administered ADHD-5-Rating Scale) has been met.
    • 01 Feb 2018 According to a Purdue Pharma media release, Health canada approved FOQUEST (methylphenidate HCl controlled-release capsules) for the treatment of ADHD in adults based on results from this study. FOQUEST is commercially available in Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top